Discover

RGEN
Repligen Corporation
181.13
1 x 181.32
2 x 191.88
bid
ask
+
0.84
0.47%
2 @ 07:30 PM
181.00 -0.13 (0.07%)
Ytd10.54%
1y51.38%
175.75
day range
182.43
102.87
52 week range
181.13
Open179.66Prev Close180.29Low175.75High182.43Mkt Cap10.22B
Vol1.10MAvg Vol1.12MEPS0.72P/E251.57Forward P/E68.63
Beta1.01Short Ratio5.12Inst. Own120.01%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-2850-d Avg146.95200-d Avg140.611yr Est185.70
Earning
DateForEstimateReportedSurprisesurprise %
2026-10-272026-090.46N/AN/AN/A
2026-07-282026-060.450.540.0920.81%
2026-05-052026-030.380.480.126.32%
2026-02-242025-120.440.490.0511.36%
2025-10-282025-090.420.460.049.52%
2025-07-292025-060.40.37-0.03-7.50%
Upgrade / Downgrade
DateFirmActionFromTo
2026-07-30Wells FargoUpgradeOverweightOverweight
2026-07-29JP MorganUpgradeOverweightOverweight
2026-07-07BenchmarkUpgradeHoldBuy
2026-07-06Evercore ISI GroupUpgradeOutperformOutperform
2026-06-03HSBCUpgradeBuyBuy
2026-05-06JP MorganUpgradeOverweightOverweight
Profile
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Insider Holder
DateNameRelationQuantityDescription
2026-03-04BYLUND JAMESChief Operating Officer25.42KStock Award(Grant)
2026-05-13DAWES KAREN ADirector92.82KStock Award(Grant)
2025-12-30DOUGLASS BRIAN ROBBOfficer8.54KStock Award(Grant)
2026-05-13EGLINTON MANNER CARRIEDirector5.46KStock Award(Grant)
2026-07-15GARLAND JASON K.Chief Financial Officer18.83KSale
2025-11-12HUNT ANTHONY JOHNDirector83.70KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Blackrock Inc.5.38M975.37M9.54%
2026-06-29FMR, LLC3.33M602.56M5.89%
2026-06-29United Capital Financial Advisors, LLC2.79M505.47M4.94%
2026-06-29Vanguard Capital Management LLC2.41M436.74M4.27%
2026-06-29Vanguard Portfolio Management LLC2.31M418.92M4.10%
2026-06-29Maverick Capital Ltd.1.98M359.46M3.52%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-07-30iShares Trust-iShares Core S&P Mid-Cap ETF1.82M329.88M3.23%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.71M309.28M3.03%
2026-03-30VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.23M223.50M2.19%
2026-03-30T. Rowe Price New Horizons Fund, Inc.1.20M217.81M2.13%
2026-05-30MFS Series Trust IV-MFS Mid Cap Growth Fund862.37K156.20M1.53%
2026-03-30T. Rowe Price All-Cap Opportunities Fd., Inc.-T. Rowe Price All-Cap Op748.46K135.57M1.33%